3,341 Shares in AstraZeneca PLC $AZNCF Purchased by Krilogy Financial LLC

Krilogy Financial LLC acquired a new stake in AstraZeneca PLC (OTCMKTS:AZNCF) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 3,341 shares of the company’s stock, valued at approximately $670,000.

Several other hedge funds have also recently added to or reduced their stakes in the business. Vaughan David Investments LLC IL purchased a new stake in shares of AstraZeneca in the fourth quarter valued at about $88,367,000. Captrust Financial Advisors acquired a new position in shares of AstraZeneca during the 4th quarter worth approximately $24,965,000. Azimuth Capital Investment Management LLC acquired a new position in shares of AstraZeneca during the 4th quarter worth approximately $20,440,000. L & S Advisors Inc purchased a new stake in AstraZeneca in the 4th quarter valued at approximately $14,863,000. Finally, Park National Corp OH purchased a new stake in AstraZeneca in the 1st quarter valued at approximately $14,462,000. 40.87% of the stock is currently owned by hedge funds and other institutional investors.

AstraZeneca Stock Performance

Shares of OTCMKTS:AZNCF opened at $187.10 on Friday. The business’s fifty day moving average price is $187.10 and its two-hundred day moving average price is $186.25. AstraZeneca PLC has a one year low of $122.26 and a one year high of $195.00.

AstraZeneca Company Profile

AstraZeneca (OTCMKTS:AZNCF) is a global biopharmaceutical company that focuses on the discovery, development, manufacturing and commercialization of prescription medicines. The company’s research and development efforts are concentrated in three main therapeutic areas: oncology; cardiovascular, renal and metabolism; and respiratory, inflammation and autoimmunity. AstraZeneca’s product portfolio includes targeted therapies for lung and breast cancers, novel agents for heart failure and chronic kidney disease, and inhaled treatments for asthma and chronic obstructive pulmonary disease.

The company was formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group, creating one of the world’s largest pharmaceutical firms.